Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

NCT05284539 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

760

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab

Sponsor

Hunan Province Tumor Hospital